SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
The Extraordinary Excursion of Dental Embed Innovation - 2If someone's always late, is it time blindness, or are they just being rude?
- 3Nations for Youngsters to Visit
- 4Watch SpaceX launch 119 payloads to orbit from California early on March 30
- 5'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 5 Bike Brands for Ordinary Use
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how
- Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- 'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- Turning to turkey’s tryptophan to boost mood? Not so fast
